ABL1 is an inclusion eligibility criterion in 6 clinical trials for diffuse large B-cell lymphoma, of which 4 are open and 2 are closed. Of the trials that contain ABL1 status and diffuse large B-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open), 4 are phase 1 (2 open), and 1 is phase 1/phase 2 (1 open) [3].

AFF1 is an inclusion eligibility criterion in 4 clinical trials for diffuse large B-cell lymphoma, of which 3 are open and 1 is closed. Of the trials that contain AFF1 status and diffuse large B-cell lymphoma as inclusion criteria, 3 are phase 1 (2 open) and 1 is phase 2 (1 open) [3].

ALK is an inclusion eligibility criterion in 12 clinical trials for diffuse large B-cell lymphoma, of which 11 are open and 1 is closed. Of the trials that contain ALK status and diffuse large B-cell lymphoma as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), 5 are phase 2 (4 open), and 3 are phase 3 (3 open) [3].

ARID1A is an inclusion eligibility criterion in 2 clinical trials for diffuse large B-cell lymphoma, of which 2 are open and 0 are closed. Of the trials that contain ARID1A status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

ASXL1 is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ASXL1 status and diffuse large B-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) [3].

ATM is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ATM status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

ATR is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ATR status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

ATRX is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ATRX status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

BAP1 is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BAP1 status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

BARD1 is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BARD1 status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

BCL2 is an inclusion eligibility criterion in 61 clinical trials for diffuse large B-cell lymphoma, of which 52 are open and 9 are closed. Of the trials that contain BCL2 status and diffuse large B-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open), 18 are phase 1 (13 open), 11 are phase 1/phase 2 (10 open), 19 are phase 2 (17 open), 3 are phase 2/phase 3 (2 open), 8 are phase 3 (8 open), and 1 is no phase specified (1 open) [3].

BCL6 is an inclusion eligibility criterion in 59 clinical trials for diffuse large B-cell lymphoma, of which 51 are open and 8 are closed. Of the trials that contain BCL6 status and diffuse large B-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open), 17 are phase 1 (13 open), 11 are phase 1/phase 2 (10 open), 19 are phase 2 (17 open), 3 are phase 2/phase 3 (2 open), 7 are phase 3 (7 open), and 1 is no phase specified (1 open) [3].

BCR is an inclusion eligibility criterion in 6 clinical trials for diffuse large B-cell lymphoma, of which 4 are open and 2 are closed. Of the trials that contain BCR status and diffuse large B-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open), 4 are phase 1 (2 open), and 1 is phase 1/phase 2 (1 open) [3].

BIRC2 is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BIRC2 status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

BIRC3 is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BIRC3 status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

BRCA1 is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

BRCA2 is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

BRIP1 is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BRIP1 status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

C11orf30 is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains C11orf30 status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

CARD11 is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CARD11 status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

CBFB is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains CBFB status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

CCND1 is an inclusion eligibility criterion in 6 clinical trials for diffuse large B-cell lymphoma, of which 4 are open and 2 are closed. Of the trials that contain CCND1 status and diffuse large B-cell lymphoma as inclusion criteria, 4 are phase 1 (2 open) and 2 are phase 1/phase 2 (2 open) [3].

CD274 is an inclusion eligibility criterion in 2 clinical trials for diffuse large B-cell lymphoma, of which 2 are open and 0 are closed. Of the trials that contain CD274 status and diffuse large B-cell lymphoma as inclusion criteria, 2 are phase 2 (2 open) [3].

CD79A is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CD79A status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

CD79B is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CD79B status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

CDK12 is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CDK12 status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

CHEK1 is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CHEK1 status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

CHEK2 is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CHEK2 status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

CREBBP is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CREBBP status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

DEK is an inclusion eligibility criterion in 4 clinical trials for diffuse large B-cell lymphoma, of which 3 are open and 1 is closed. Of the trials that contain DEK status and diffuse large B-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) and 3 are phase 1 (2 open) [3].

ELL is an inclusion eligibility criterion in 4 clinical trials for diffuse large B-cell lymphoma, of which 3 are open and 1 is closed. Of the trials that contain ELL status and diffuse large B-cell lymphoma as inclusion criteria, 3 are phase 1 (2 open) and 1 is phase 2 (1 open) [3].

EP300 is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains EP300 status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

ERCC2 is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ERCC2 status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

ERCC3 is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ERCC3 status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

ERCC4 is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ERCC4 status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

ERCC5 is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ERCC5 status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

ERCC6 is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ERCC6 status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

EZH2 is an inclusion eligibility criterion in 3 clinical trials for diffuse large B-cell lymphoma, of which 2 are open and 1 is closed. Of the trials that contain EZH2 status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

FANCA is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FANCA status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCB is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FANCB status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCC is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FANCC status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCD2 is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FANCD2 status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCE is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FANCE status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCF is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FANCF status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCG is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FANCG status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCI is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FANCI status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCL is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FANCL status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCM is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FANCM status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FGFR3 is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FLT3 is an inclusion eligibility criterion in 5 clinical trials for diffuse large B-cell lymphoma, of which 4 are open and 1 is closed. Of the trials that contain FLT3 status and diffuse large B-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open), 3 are phase 1 (2 open), and 1 is phase 1/phase 2 (1 open) [3].

HDAC1 is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains HDAC1 status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

HDAC2 is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains HDAC2 status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

HRAS is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and diffuse large B-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) [3].

IGH is an inclusion eligibility criterion in 6 clinical trials for diffuse large B-cell lymphoma, of which 4 are open and 2 are closed. Of the trials that contain IGH status and diffuse large B-cell lymphoma as inclusion criteria, 4 are phase 1 (2 open) and 2 are phase 1/phase 2 (2 open) [3].

IRF4 is an inclusion eligibility criterion in 2 clinical trials for diffuse large B-cell lymphoma, of which 2 are open and 0 are closed. Of the trials that contain IRF4 status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

JAK2 is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains JAK2 status and diffuse large B-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) [3].

KIT is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains KIT status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

KMT2A is an inclusion eligibility criterion in 6 clinical trials for diffuse large B-cell lymphoma, of which 5 are open and 1 is closed. Of the trials that contain KMT2A status and diffuse large B-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open), 3 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

KRAS is an inclusion eligibility criterion in 2 clinical trials for diffuse large B-cell lymphoma, of which 2 are open and 0 are closed. Of the trials that contain KRAS status and diffuse large B-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) and 1 is phase 1 (1 open) [3].

MAF is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MAF status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MAFB is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MAFB status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MDM2 is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MDM2 status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MDM4 is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MECOM is an inclusion eligibility criterion in 4 clinical trials for diffuse large B-cell lymphoma, of which 3 are open and 1 is closed. Of the trials that contain MECOM status and diffuse large B-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) and 3 are phase 1 (2 open) [3].

MLF1 is an inclusion eligibility criterion in 2 clinical trials for diffuse large B-cell lymphoma, of which 1 is open and 1 is closed. Of the trials that contain MLF1 status and diffuse large B-cell lymphoma as inclusion criteria, 2 are phase 1 (1 open) [3].

MLH1 is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MLH1 status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MLH3 is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MLH3 status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MLLT1 is an inclusion eligibility criterion in 4 clinical trials for diffuse large B-cell lymphoma, of which 3 are open and 1 is closed. Of the trials that contain MLLT1 status and diffuse large B-cell lymphoma as inclusion criteria, 3 are phase 1 (2 open) and 1 is phase 2 (1 open) [3].

MLLT10 is an inclusion eligibility criterion in 4 clinical trials for diffuse large B-cell lymphoma, of which 3 are open and 1 is closed. Of the trials that contain MLLT10 status and diffuse large B-cell lymphoma as inclusion criteria, 3 are phase 1 (2 open) and 1 is phase 2 (1 open) [3].

MLLT3 is an inclusion eligibility criterion in 4 clinical trials for diffuse large B-cell lymphoma, of which 3 are open and 1 is closed. Of the trials that contain MLLT3 status and diffuse large B-cell lymphoma as inclusion criteria, 3 are phase 1 (2 open) and 1 is phase 2 (1 open) [3].

MLLT4 is an inclusion eligibility criterion in 4 clinical trials for diffuse large B-cell lymphoma, of which 3 are open and 1 is closed. Of the trials that contain MLLT4 status and diffuse large B-cell lymphoma as inclusion criteria, 3 are phase 1 (2 open) and 1 is phase 2 (1 open) [3].

MRE11A is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MRE11A status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MSH2 is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MSH2 status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MSH3 is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MSH3 status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MSH6 is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MUTYH is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MUTYH status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MYC is an inclusion eligibility criterion in 70 clinical trials for diffuse large B-cell lymphoma, of which 57 are open and 13 are closed. Of the trials that contain MYC status and diffuse large B-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open), 21 are phase 1 (15 open), 13 are phase 1/phase 2 (12 open), 23 are phase 2 (18 open), 3 are phase 2/phase 3 (2 open), 8 are phase 3 (8 open), and 1 is no phase specified (1 open) [3].

MYCN is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MYCN status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

MYD88 is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MYD88 status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

MYH11 is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MYH11 status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

NBN is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains NBN status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

NFKBIA is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains NFKBIA status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

NPM1 is an inclusion eligibility criterion in 3 clinical trials for diffuse large B-cell lymphoma, of which 1 is open and 2 are closed. Of the trials that contain NPM1 status and diffuse large B-cell lymphoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 2 (0 open) [3].

NRAS is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and diffuse large B-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) [3].

NRIP3 is an inclusion eligibility criterion in 4 clinical trials for diffuse large B-cell lymphoma, of which 3 are open and 1 is closed. Of the trials that contain NRIP3 status and diffuse large B-cell lymphoma as inclusion criteria, 3 are phase 1 (2 open) and 1 is phase 2 (1 open) [3].

NUP214 is an inclusion eligibility criterion in 4 clinical trials for diffuse large B-cell lymphoma, of which 3 are open and 1 is closed. Of the trials that contain NUP214 status and diffuse large B-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) and 3 are phase 1 (2 open) [3].

PALB2 is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PALB2 status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

PARP1 is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PARP1 status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

PARP2 is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PARP2 status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

PBX1 is an inclusion eligibility criterion in 3 clinical trials for diffuse large B-cell lymphoma, of which 3 are open and 0 are closed. Of the trials that contain PBX1 status and diffuse large B-cell lymphoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [3].

PMS1 is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PMS1 status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

PMS2 is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PMS2 status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

POLD1 is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains POLD1 status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

POLE is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains POLE status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

POLQ is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains POLQ status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

PPP2R1A is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PPP2R1A status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

PPP2R2A is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PPP2R2A status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

PRKDC is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PRKDC status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

RAD50 is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains RAD50 status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

RAD51 is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51 status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

RAD51B is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51B status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

RAD51C is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51C status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

RAD51D is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51D status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

RAD54L is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains RAD54L status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

RPN1 is an inclusion eligibility criterion in 4 clinical trials for diffuse large B-cell lymphoma, of which 3 are open and 1 is closed. Of the trials that contain RPN1 status and diffuse large B-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) and 3 are phase 1 (2 open) [3].

RUNX1 is an inclusion eligibility criterion in 2 clinical trials for diffuse large B-cell lymphoma, of which 1 is open and 1 is closed. Of the trials that contain RUNX1 status and diffuse large B-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) and 1 is phase 1 (0 open) [3].

RUNX1T1 is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains RUNX1T1 status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

SLX4 is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains SLX4 status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

SMARCB1 is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

STAG2 is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains STAG2 status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

STK11 is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains STK11 status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

TCF3 is an inclusion eligibility criterion in 3 clinical trials for diffuse large B-cell lymphoma, of which 3 are open and 0 are closed. Of the trials that contain TCF3 status and diffuse large B-cell lymphoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [3].

TNFAIP3 is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains TNFAIP3 status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

TP53 is an inclusion eligibility criterion in 5 clinical trials for diffuse large B-cell lymphoma, of which 4 are open and 1 is closed. Of the trials that contain TP53 status and diffuse large B-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open), 3 are phase 1 (2 open), and 1 is phase 2 (1 open) [3].

WHSC1 is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains WHSC1 status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

XRCC1 is an inclusion eligibility criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains XRCC1 status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].